ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
Clinical trial NCT06463327 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06463327
- Sponsor
- TC Biopharm
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-01
- Primary completion
- 2026-06-01
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.